The clinical efficacy of ticagrelor in the treatment of patients with acute coronary syndrome

Abstract

Objective To investigate the clinical efficacy and safety of ticagrelor in the treatment of patients with acute coronary syndrome(ACS). Methods From January 2016 to June 2017, 112 patients with ACS in the Central Hospital of Maanshan were selected as study objects, and according to the digital table they were randomized divided into two groups: ticagrelor group(n=57) and clopidogrel group(n=55). The clopidogrel group received clopidogrel treatment, and the clopidogrel group was treated with clopidogrel.The time of short-term curative effect was 3 months after taking medcine.The differences of platelet inhibition rate, efficacy of platelet inhibition, main adverse cardiovascular events and hemorrhage complication in medication after 1d and 3 months after PCI of patients in two groups were observed. Results The platelet inhibition rate and efficacy of platelet inhibition in medication after 1 d and 3 months after PCI in the ticagrelor group were (83.2±15.4)% and (78.4±19.6)%, respectively, which were significantly higher than those in the clopidogrel group[(69.5±19.9)% and (41.3±14.6)%](t=2.555, 4.468, all P 0.05). Conclusion Compared with clopidogrel, the application of ticagrelor in the treatment of ACS is more efficient and safe. Key words: Coronary disease; Ticagrelor; Clopidogrel; Controlled clinical trial